Why Invest

We develop products and solutions that make life better – and have been successfully doing so for over 300 years. And when you’ve prospered for centuries as we have, you must have done a few things right.

It’s a great idea to invest in us – and here’s why

- We continue unfolding and developing our entrepreneurial potential to make the best use of the many new opportunities the market offers.
- We are aiming for quality growth, where sales increase faster than costs.
- Our growth opportunities result from innovations and from acquisitions strengthening our presence in important markets.
- This is supported by financial discipline including a strong cash flow generation and a long-term margin of >30%.
- By achieving sustainable growth, we aim to create value – for our company and for society.
- Our focus lies on three business sectors, Healthcare, Life Science and Electronics.
- In all sectors, we have the pioneering knowledge and experience needed to work with customers and to develop new products that improve the quality of life for patients, furthering the success of our customers and helping to meet global challenges.
- At the same time, operating in these business sectors enables us to spread the entrepreneurial risk of our owners.
- We actively manage our opportunities and risks as these relate to innovation, finances, supply chains, sustainability, and reputation in order to also secure our long-term business success.
- Our products and markets are highly profitable businesses: They include margins of 30% or more, resulting from leadership in growing industries and markets.
- Leveraging of niche markets’ exposure and developing specialty products together with our approach to encourage innovations further support our business setup.
- This business model will continuously open up potential to expand in the future as it did in the past.
- Many successful companies adapt to changes in society, research and technology – we initiate and shape those changes.
- Our market presence is characterized by cutting-edge innovations in research and development, expertise in manufacturing, and strong customer proximity.
- We believe that the potential of innovation can best be set free in the context of open processes, co-operations, alliances and partnerships – an environment that we will continue to foster with our newly built innovation center.
- A sustainable dividend policy that allows shareholders to participate in our economic success is a key factor in our relationship with the capital market.
- We are committed to transparency, which means best practice reporting on sustainability and corporate governance.
- Awards in the past years show the appreciation of our efforts in transparent and active capital market communication.

Related News

View All News

Press Releases

Merck KGaA, Darmstadt, Germany, Collaborates with Acceleration Consortium on ...

AI-driven experimentation planner BayBE (Bayesian Back End) by us and Acceleration Consortium is available open-source on GitHub

2023/12/06
Press Releases

MilliporeSigma Launches First Ever AI Solution to Integrate Drug Discovery ...

AIDDISON™ software-as-a-service platform bridges the gap between virtual molecule design and real-world manufacturing.

2023/12/05
Press Releases

Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib ...

Two Phase III EVOLUTION clinical trials of evobrutinib did not meet their primary endpoints.

2023/12/05

Share Price

Check Share Price

Share Price

Our interactive Share Price Tool provides you with all the information you need. You can retrace our development within the last ten years or follow it in real time – or compare our share price to various indices.

Financials

Our Financial Reporting Center offers you the opportunity to select from financial data on an annual or quarterly basis.

Why Invest

Explore More

Explore More

It’s a great idea to invest in us – and here’s why

Related News

Merck KGaA, Darmstadt, Germany, Collaborates with Acceleration Consortium on ...

MilliporeSigma Launches First Ever AI Solution to Integrate Drug Discovery ...

Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib ...

Share Price

Share Price

Financials

Financials